BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26417636)

  • 21. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.
    Iqbal J; Ginsburg OM; Wijeratne TD; Howell A; Evans G; Sestak I; Narod SA
    Cancer Treat Rev; 2012 Jun; 38(4):318-28. PubMed ID: 21775065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen in ductal carcinoma in situ.
    Daly MB
    Semin Oncol; 2006 Dec; 33(6):647-9. PubMed ID: 17145343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemoprevention of breast cancer.
    O'Regan RM
    Cancer Treat Res; 2000; 103():183-207. PubMed ID: 10948447
    [No Abstract]   [Full Text] [Related]  

  • 26. Bone builder vs. breast cancer.
    Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491
    [No Abstract]   [Full Text] [Related]  

  • 27. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial.
    Nicolini A; Carpi A
    Biomed Pharmacother; 2005 Jun; 59(5):253-63. PubMed ID: 15913946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer.
    American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
    Obstet Gynecol; 2006 Jun; 107(6):1475-8. PubMed ID: 16738185
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer.
    Seo JH; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):261-6. PubMed ID: 18365197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-dose tamoxifen in breast cancer bone metastasis.
    Stathopoulos GP; Trafalis D
    J BUON; 2013; 18(2):532-4. PubMed ID: 23818373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endometrial damage by antiestrogens in a postmenopausal breast cancer patient.
    Ceci O; Bettocchi S; Marello F; Pellegrino A; Impedovo L; Di Venere R
    Acta Obstet Gynecol Scand; 2002 Feb; 81(2):174-5. PubMed ID: 11942911
    [No Abstract]   [Full Text] [Related]  

  • 32. The duration of adjuvant tamoxifen therapy.
    Bilimoria MM; Jordan VC
    Cancer Treat Res; 1998; 94():181-93. PubMed ID: 9587688
    [No Abstract]   [Full Text] [Related]  

  • 33. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer.
    Lewis JD; Chagpar AB; Shaughnessy EA; Nurko J; McMasters K; Edwards MJ
    Cancer; 2010 May; 116(10):2307-15. PubMed ID: 20209619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer adjuvant endocrine therapy.
    Cigler T; Goss PE
    Cancer J; 2007; 13(3):148-55. PubMed ID: 17620763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two good choices to prevent breast cancer: great taste, less filling.
    Hortobagyi GN; Brown PH
    Cancer Prev Res (Phila); 2010 Jun; 3(6):681-5. PubMed ID: 20522797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of postmenopausal breast cancer patients following discontinuation of tamoxifen therapy.
    Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
    Maturitas; 2008 Apr; 59(4):387-93. PubMed ID: 18490117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duration of adjuvant endocrine therapy of breast cancer: how much is enough?
    Ward JH
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):51-5. PubMed ID: 19952743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].
    Ricart JJ
    Medicina (B Aires); 2004; 64(1):66-72. PubMed ID: 15034961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.